Platelet
Function in Coronary Artery Disease, Scientific Council,
University of Massachusetts Medical School, Principal Investigator,
7/1/94-6/30/99 $97,000 Direct costs
A
Phase II, Placebo-controlled, Multicenter Study of TLC C-53
as an Adjunct to Thrombolytic Therapy in Patients with Acute
Myocardial Infarction. Liposomal Intervention Followed by
Thrombolysis (LIFT). The Liposome Company, 8/1/95-12/1/96,
Principal Investigator, $88,000 Direct costs
The
Effects of TLC C-53 on Platelet and Leukocyte Function in
Patients Receiving Thrombolytic Therapy for Acute Myocardial
Infarction. The Liposome Company, 8/1/95-12/1/96, Principal
Investigator, $34,000 Direct costs
Antiplatelet
Therapy or Lovenox Plus Antiplatelet Therapy for Patients
with an Increased Risk of Stent Thrombosis. Rhone Poulec
Rorer, 4/1/95-12/1/96, Principal Investigator, $40,800 Direct
Costs
Platelet
Function in Congestive Heart Failure Scientific Council,
University of Massachusetts Medical School, Principal Investigator,
7/1/95-6/30/96 $10,000 Direct costs
Diagnosis
of Acute Myocardial Infarction by P-Selectin Profile and
its Diagnostic Value in Acute Coronary Syndromes. Centocor
Diagnostics of PA, Inc., 11/97-9/98, Co-Principal Investigator,
$112,500 Direct Costs
Diagnosis
of Acute Myocardial Infarction by Measurement of Circulating
Monocyte-Platelet Aggregates. CompuCyte Corp., 11/97-9/98,
Principal Investigator, $43,750 Direct Costs
Prediction
of Cardiac Events after Percutaneous Coronary Intervention
by Measurement of Circulating Monocyte-Platelet Aggregates
CompuCyte Corp., 11/97-9/98, Principal Investigator, $37,500
Direct Costs
A
Study to Assess the Equivalence of the Accumetrics Rapid
Platelet Function Assay (RPFA) in Patients Who are Undergoing
Coronary Intervention Procedures to a GPIIb-IIIa Receptor
Blockade Assay Using I125 Abciximab. Accumetrics, Inc.,
8/98-2/99, Co-Principal Investigator $73,000 Direct costs
The
Effects of GPIIb-IIIa Antagonists on In-Vitro Platelet Procoagulant
Activity and Leukocyte-Platelet Aggregation. Centocor, Inc.,
2/98-1/99, Principal Investigator, $23,000 Direct costs.
Diagnosis
of Acute Myocardial Infarction by Measurement of Circulating
Monocyte-Platelet Aggregates (Phase II). CompuCyte Corp.,
Principal Investigator, 2/3/99-9/3/99 $168,874 Direct costs
Diagnosis
of Stroke by Measurement of Circulating Monocyte-Platelet
Aggregates. CompuCyte Corp., Principal Investigator, 7/13/99-4/13/00
$57,624 Direct costs
The
Effects of Retaplase and Alteplase on Platelet Function
in Acute Myocardial Infarction, Centocor, Inc, Principal
Investigator $143,466 Direct costs
In
Vivo Effects of Abciximab on Platelet and Leukocyte Activation,
Leukocyte-Platelet Aggregation, Platelet Procoagulant Activity,
and Platelet-Derived Microparticles in Patients with Unstable
Angina/Non-Q-Wave Myocardial Infarction: A Case-Control
Study, Centocor, Inc, Principal Investigator, $155,456 Direct
costs
In
Vivo Effects of Abciximab on Platelet-Endothelial Cell Adhesion
in Patients with Unstable Angina/Non-Q-Wave Myocardial Infarction:
A Case-Control Study, Centocor, Inc, Principal Investigator,
$32,378 Direct costs
A
Blinded, Randomized Comparative Trial of Dalteparin versus
Unfractionated Heparin in Conjunction with Abciximab Platelet
GP IIb/IIIa Inhibition During and Following Elective Percutaneous
Coronary Intervention (Platelet function core laboratory).
Principal Investigator, Pharmacia & Upjohn, $56,905, Direct
costs
Placebo
Controlled Randomized Administration of Reduced Dose Abciximab
Prior to Percutaneous Coronary Intervention in Patients
Receiving Intravenous Abciximab Infusion Following Pharmacologic
Reperfusion of Acute Myocardial Infarction. (Platelet function
core laboratory). Principal Investigator, Centocor, Inc.
$23,655 Direct costs
An
Open Labelled, Randomized, Parallel, Dose-Finding (Dose-Ranging)
Study of TNK-tPA in Combination with AGGRASTAT in the Treatment
of Acute Myocardial Infarction (FASTER Trial). Principal
Investigator, Merck, Inc. $57,168 Direct costs.
Assessment
of Platelet Function in Subjects Receiving Clopidogrel or
Ticlopidine Accumetrics Protocol # P95049. Principal Investigator,
Accumetrics, Inc. $23,000 Direct costs
Assessment
of Platelet Function in Subjects Receiving Eptifibatide
Accumetrics Protocol # P95038. Principal Investigator, Accumetrics,
Inc. $26,000 Direct costs
